3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Colorectal Neoplasms
26
Pancreatic Neoplasms
12
Stomach Neoplasms
11
Colonic Neoplasms
9
Rectal Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Esophageal Neoplasms
7
Adenocarcinoma Of Esophagus
7
Burkitt Lymphoma
6
Neoplasms
5
Cholangiocarcinoma
5
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Urinary Bladder Neoplasms
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Leukemia, Biphenotypic, Acute
2
Leukemia
2
Gallbladder Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Urachal cancer
1
Unresectable Colorectal Cancer
1
Interventions
pembrolizumab
10
Cisplatin
7
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Specimen Handling
5
Paclitaxel
5
Brachytherapy
5
Fluorodeoxyglucose F18
4
dostarlimab
3
atezolizumab
3
Trastuzumab
3
Radiation
3
Platinum
3
Nivolumab
3
Human Papillomavirus DNA Tests
3
Docetaxel
3
Colposcopy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tislelizumab
2
spartalizumab
2
olaparib
2
human papillomavirus vaccine, L1 type 16, 18
2
durvalumab
2
Vaccines
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiation Dose Hypofractionation
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Uterine Cervical Neoplasms
×
Leucovorin
×
Clear all
NCT05891171
2026-03-31
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled